Gene therapy (AAV vector) · Gene replacement · developed by Lexeo Therapeutics
LX1001 is a serotype rh.10 adeno-associated virus (AAV) gene transfer vector that carries the cDNA for human APOE2. It is studied in Alzheimer disease, including early onset Alzheimer disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03634007 | Phase 1/2 | Alzheimer Disease | Completed | LXEO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer DiseaseEarly Onset Alzheimer Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LXEO page.
See LXEO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LXEO catalysts and pipeline →